Eling, Laura; Kefs, Samy; Keshmiri, Sarvenaz; Balosso, Jacques; Calvet, Susan; Chamel, Gabriel; Drevon-Gaud, Renaud; Flandin, Isabelle; Gaudin, Maxime; Giraud, Lucile; Laissue, Jean Albert; Pellicioli, Paolo; Verry, Camille; Adam, Jean-François; Serduc, Raphaël (2024). Neuro-Oncologic Veterinary Trial for the Clinical Transfer of Microbeam Radiation Therapy: Acute to Subacute Radiotolerance after Brain Tumor Irradiation in Pet Dogs. Cancers, 16(15) MDPI AG 10.3390/cancers16152701
|
Text
cancers-16-02701.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (5MB) | Preview |
Synchrotron Microbeam Radiation Therapy (MRT) has repeatedly proven its superiority compared with conventional radiotherapy for glioma control in preclinical research. The clinical transfer phase of MRT has recently gained momentum; seven dogs with suspected glioma were treated under clinical conditions to determine the feasibility and safety of MRT. We administered a single fraction of 3D-conformal, image-guided MRT. Ultra-high-dose rate synchrotron X-ray microbeams (50 µm-wide, 400 µm-spaced) were delivered through five conformal irradiation ports. The PTV received ~25 Gy peak dose (within microbeams) per port, corresponding to a minimal cumulated valley dose (diffusing between microbeams) of 2.8 Gy. The dogs underwent clinical and MRI follow-up, and owner evaluations. One dog was lost to follow-up. Clinical exams of the remaining six dogs during the first 3 months did not indicate radiotoxicity induced by MRT. Quality of life improved from 7.3/10 [±0.7] to 8.9/10 [±0.3]. Tumor-induced seizure activity decreased significantly. A significant tumor volume reduction of 69% [±6%] was reached 3 months after MRT. Our study is the first neuro-oncologic veterinary trial of 3D-conformal Synchrotron MRT and reveals that MRT does not induce acute to subacute radiotoxicity in normal brain tissues. MRT improves quality of life and leads to remarkable tumor volume reduction despite low valley dose delivery. This trial is an essential step towards the forthcoming clinical application of MRT against deep-seated human brain tumors.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Laissue, Jean |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
2072-6694 |
Publisher: |
MDPI AG |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
12 Aug 2024 13:46 |
Last Modified: |
12 Aug 2024 13:56 |
Publisher DOI: |
10.3390/cancers16152701 |
PubMed ID: |
39123429 |
Uncontrolled Keywords: |
Synchrotron Microbeam Radiation Therapy acute to subacute radiation effects clinical transfer phase dog brain tumor |
BORIS DOI: |
10.48350/199625 |
URI: |
https://boris.unibe.ch/id/eprint/199625 |
Actions (login required)
 |
Edit item |